Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

Original reporting
Published Nov 16, 2026, 11:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$KMTS
Bullish
high confidence
Mentioned
$KMTS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KMTSBullishMed
01

Why it matters

The data represent the first public disclosure of the device's efficacy, likely improving investor sentiment and supporting a price rally.

02

Market read

First‑time release of positive clinical trial data for a U.S. listed medical‑device company, offering material insight for traders.

03

What to watch

Potential competition from other wearable defibrillators and the need for insurance coverage.

Relevance 8/10Novelty 8/10Timing: today

Background

Kestra Medical Technologies (NASDAQ:KMTS) announced primary results from its post‑approval study of the ASSURE wearable cardioverter‑defibrillator, showing 100% shock conversion and a low inappropriate‑shock rate.

Company-level read

Ticker impact

$KMTSBullishHigh confidence
Context

Kestra Medical Technologies reported FDA‑mandated post‑approval study showing 100% shock conversion and low inappropriate‑shock rate for its ASSURE wearable defibrillator.

Expected impact

likely upward pressure as investors price in the successful trial results.

Evidence & confidence

First disclosure of full‑shock conversion and reduced inappropriate‑shock rate provides material, novel data for a micro‑cap medical‑device company.

Market effects

Strengthens the wearable cardiac device sector and may boost peer valuations.

U.S. market focus as the study enrolled patients across 35 states.

Limited; primarily relevant to U.S. investors and medical‑device niche.

Counterpoint

If reimbursement or adoption hurdles persist, the trial success may not translate into sales.

Key entities

  • Kestra Medical Technologies

    Developer of the ASSURE wearable cardioverter‑defibrillator.

  • ASSURE Device

    Wearable cardioverter‑defibrillator evaluated in the study.

Related articles

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.